0001048477-24-000002.txt : 20240111 0001048477-24-000002.hdr.sgml : 20240111 20240111144039 ACCESSION NUMBER: 0001048477-24-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240108 FILED AS OF DATE: 20240111 DATE AS OF CHANGE: 20240111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES CENTRAL INDEX KEY: 0001221590 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 24528981 MAIL ADDRESS: STREET 1: 925 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 wk-form4_1705002030.xml FORM 4 X0508 4 2024-01-08 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO STREET SAN RAFAEL CA 94901 1 0 0 0 1 Common Stock 2024-01-08 4 L 0 50 99.0518 A 425162 D Common Stock 2024-01-09 4 M 0 10000 63.10 A 435162 D Common Stock 2024-01-09 4 S 0 10000 98.19 D 425162 D Common Stock 2024-01-10 4 M 0 10000 63.10 A 435162 D Common Stock 2024-01-10 4 S 0 10000 96.38 D 425162 D Common Stock 247333 I Shares held by Jean-Jacques Bienaime Family Trust Common Stock 100 I Shares held as UTMA custodian for child 1 Common Stock 100 I Shares held as UTMA custodian for child 2 Stock Option (Right to Buy Common Stock) 63.10 2024-01-09 4 M 0 10000 0 D 2014-12-04 2024-06-03 Common Stock 10000 171000 D Stock Option (Right to Buy Common Stock) 63.10 2024-01-10 4 M 0 10000 0 D 2014-12-04 2024-06-03 Common Stock 10000 161000 D The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Tae Sang Yoo, Attorney-in-Fact 2024-01-11